Background: Amplification and rearrangement of the epidermal growth factor receptor (EGFR) gene is frequently associated with malignant gliomas. One type of EGFR mutation in primary gliomas results in overexpression of an aberrant EGFR messenger RNA (mRNA) that lacks sequences of exons II through VI of the human EGFR gene. We observed that the aberrantly spliced EGFR mRNA contains a ribozyme cleavable sequence (5-AAG GUA AUU-3) created by the joining of EGFR exon I to exon VII. We hypothesized that an appropriately designed ribozyme RNA could mediate site-specific cleavage of the aberrant EGFR mRNA and reduce the growth of aberrant EGFR-producing tumor cells. Methods: We synthesized aberrant EGFR mRNA substrates and a sequence-specific hammerhead ribozyme (abEGFR-rib) to examine the ribozyme's activity in vitro. We also constructed an abEGFR-rib plasmid and introduced it into ERM5-1 cells, which are murine NIH3T3 cells transfected to express an aberrant EGFR complementary DNA. We measured the growth potential of the cotransfected cells in culture and in nude mice. Results: The synthesized abEGFR-rib efficiently and specifically cleaved aberrant EGFR mRNA substrates in vitro. Expression of the transfected abEGFR-rib suppressed expression of aberrant EGFR mRNA in ERM5-1 cells and reduced the growth of tumors formed by the cotransfected cells in nude mice. Finally, the incorporation of bromodeoxyuridine, a measure of mitotic activity, was also decreased in abEGFR-ribproducing ERM5-1 cells in vivo. Conclusion: Ribozymes targeted to aberrant EGFR mRNA can inhibit the growth of tumors formed by cells that express this mRNA. [J Natl Cancer Inst 1998;90:581-7]
Background: Amplification and rearrangement of the epidermal growth factor receptor (EGFR) gene is frequently associated with malignant gliomas. One type of EGFR mutation in primary gliomas results in overexpression of an aberrant EGFR messenger RNA (mRNA) that lacks sequences of exons II through VI of the human EGFR gene. We observed that the aberrantly spliced EGFR mRNA contains a ribozyme cleavable sequence (5-AAG GUA AUU-3) created by the joining of EGFR exon I to exon VII. We hypothesized that an appropriately designed ribozyme RNA could mediate site-specific cleavage of the aberrant EGFR mRNA and reduce the growth of aberrant EGFR-producing tumor cells. Methods: We synthesized aberrant EGFR mRNA substrates and a sequence-specific hammerhead ribozyme (abEGFR-rib) to examine the ribozyme's activity in vitro. We also constructed an abEGFR-rib plasmid and introduced it into ERM5-1 cells, which are murine NIH3T3 cells transfected to express an aberrant EGFR complementary DNA. We measured the growth potential of the cotrans- The epidermal growth factor receptor (EGFR) gene encodes a Src family receptor tyrosine kinase with oncogenic potential (1, 2) . The EGFR gene is rearranged and overexpressed in human glioblastomas (3, 4) . Three types (I to III) of mutant EGFR genes were reported (5) , of which the type III mutation represents an 801 nucleotide deletion in EGFR messenger RNA (mRNA) (6) (7) (8) . Approximately 32% of all primary human glioblastomas with EGFR amplification have this alteration (7) . Furthermore, 17% of malignant gliomas possess this mutation (9) . Aberrant EGFR mRNA expression may be associated with carcinogenesis because NIH3T3 cells transfected with an EGFR complementary DNA (cDNA) harboring the type III mutation show transforming activity (6) . Recently, we detected the aberrant type III EGFR (abEGFR) transcript in proliferating glioma cells using in situ hybridization (10) . Taken together, these findings suggest that expression of aberrant EGFR mRNA plays a significant role in the continuous and aggressive growth of malignant gliomas.
Ribozymes are catalytic antisense RNAs that cleave RNA substrates in a sequence-specific manner (11) . The hammerheadtype ribozyme was originally discovered in satellite RNA of tobacco ringspot virus (12, 13) and functions in that system in a cis-acting manner. Studies (14, 15) showed that recombinant hammerhead-type ribozymes could also function in trans, with the potential for decreasing levels of specific gene transcripts. Targeted suppression of specific gene expression by ribozymes has been reported (16, 17) , including activated ras and truncated bcr-abl genes (18, 19) . The abEGFR mRNA contains the cleavage site sequence 5Ј-AAG GUA AUU-3Ј. Thus, the type III EGFR mRNA is cleavable at the junction of the truncated molecule (exon I spliced to exon VII) by the ribozyme. In this study, we evaluated the efficiency of ribozyme-mediated cleavage of abEGFR mRNA under different conditions in vitro and examined the role of ribozymes on the growth of transformed cell lines in vivo.
Materials and Methods

Ribozyme Constructs
We constructed a hammerhead ribozyme to specifically cleave abEGFR RNA in the substrate-ribozyme complex (Fig. 1, A) . The DNA templates for in vitro transcription of the RNA substrate and the hammerhead ribozyme (Fig. 1, B and C) were synthesized by 30 cycles of the polymerase chain reaction (PCR) (denaturation at 94°C for 90 seconds, annealing at 60°C for 90 seconds, and extension at 72°C for 90 seconds), using 5 U Taq DNA polymerase (Perkin Elmer Biosystems Division, Foster City, CA) using the following primers: (R1) 5Ј-TAATACGACTCACTATAGGAAAAGAAAGGTAATTA-3Ј and (R2) 5Ј-TCACCACATAATTACCTTT-3Ј for the abEGFR RNA substrate and (Rb3) 5Ј-TAATACGACTCACTATAGTCACCACATAATCTGATGAG-3Ј and (Rb4) 5Ј-GAAAAGAAAGGTTTCGTCCTCACGGACTCATCAGATT-3Ј for the ribozyme (abEGFR-rib). The R1 and R2 primer sequences were derived from the aberrant splice junction site connecting exons I and VII of the EGFR gene. The Rb3 and Rb4 primer sequences were derived from the hammerhead ribozyme and sequences complementary to abEGFR mRNA. A disabled hammerhead ribozyme (dis-abEGFR-rib) was also synthesized by PCR with the following primers: (Rb5) 5Ј-TAATACGACTCACTATAGTCACCA-CATAATCTAATGAG-3Ј and (Rb6) 5Ј-GAAAAGAAAGGTTTCGTCCT-CACGGACTCATTAGATT-3Ј. The dis-abEGFR-rib contained a single base change (G to A; Fig. 1, A) in the catalytic core compared with abEGFR-rib sequence.
Following amplification, the PCR products were fractionated through a 3% composite agarose gel (2% NuSieve, 1% Seakem) (FMC Corp., Rockland, ME), purified by DE52 (Whatman, Maidstone, U.K.) ion-exchange chromatography, and used as templates for T7 RNA polymerase (Stratagene, La Jolla, CA) catalyzed in vitro transcription (20) . For cleavage studies, the ribozymes abEGFR-rib or dis-abEGFR-rib and 25 base abEGFR substrate RNAs were labeled using [␣- to the supplier's recommendation. The RNA substrate and ribozyme transcripts were then fractionated through TBE (i.e., 90 mM Tris-borate buffer [pH 8.0] and 2 mM EDTA) and 12% polyacrylamide gels, and the products were recovered in 1% sodium dodecyl sulfate, 0.5 M CH 3 COONH 4 , and 1 mM EDTA. Cleavage reactions were performed by mixing 2 pmol of abEGFR-rib or dis-abEGFR-rib RNA combined with 2 pmol of abEGFR RNA and heated at 95°C for 2 minutes and then quickly cooled on ice. Aliquots of the 32 P-labeled double-stranded RNAs were added to prepare 10 L reaction volumes. Individual reaction mixtures were incubated under different conditions (Mg 2+ concentration: 0-40 mM; reaction time: 1 minute to 18 hours; RNA substrate/ribozyme molar ratio: 1-100; at 37°C). The cleavage products were resolved on denaturing 6% TBE polyacrylamide gels and detected by autoradiography (Kodak X-OMAT AR).
Ribozyme-Producing Cells
For producing abEGFR-rib or dis-abEGFR-rib in cells, we constructed new ribozyme and disabled ribozyme DNAs by PCR and introduced them into an expression vector (pH␤Apr-1) (21, 22) . Briefly, PCR was performed using the following primer pairs and each primer's partial complementary base pairing: (R25) 5Ј-GGAATTCAGCTGTCGACACATAATCTGATGAGTCCGTGAG-3Ј, (R26) 5Ј-GGAATTCAAGCTTAGAAAGGTTTCGTCCTCACGGACTC-3Ј for abEGFR-rib and primer (R27) 5Ј-GGAATTCAGCTGTCGACA-CATAATCTAATGAGTCCGTGAG-3Ј, primer R26 for dis-abEGFR-rib. Following appropriate restriction endonuclease digestion, the PCR products were directionally subcloned into the HindIII and Sal I restriction sites of the eukaryotic expression plasmid pH␤Apr-1 containing a selectable hygromycin resistance gene (derived from pCEP4, Invitrogen, Leek, The Netherlands) (Fig. 2) .
ERM5-1 cells were established from NIH3T3 cells by transfection with the abEGFR cDNA expression vector (6) . The ERM5-1 cells were maintained in Dulbecco's modified Eagle medium (DMEM; Sigma Chemical Co., St. Louis, MO) containing 6% fetal calf serum (IBL, Fujioka, Japan) and supplemented with penicillin (100 g/ml) and streptomycin (100 g/mL). Transfection with abEGFR-rib or dis-abEGFR-rib constructs was performed by a calcium- Fig. 1 . Primary sequence and predicted structure of the synthetic ribozyme, substrates, and the resulting cleavage products. A) Schematic structure of the aberrant epidermal growth factor receptor (EGFR) substrate-ribozyme (abEGFR-rib) complex. Arrowhead indicates the cleavage site adjacent to the junction between exons I and VII present in aberrant EGFR messenger RNA (mRNA). The guanine nucleotide that was changed to adenine to create the disabled ribozyme (dis-abEGFR-rib) is highlighted. Polymerase chain reaction (PCR) primers used to synthesize aberrant EGFR mRNA. B) The sense primer R1 (35 mer, 5Ј-TAATACGACTCACTATAGGAAAAGAAAGGTAATTA-3Ј) includes a T7 RNA polymerase promoter sequence, and the antisense primer R2 (19 mer, 5Ј-TCACCACATAATTACCTTT-3Ј) was used for PCR-catalyzed synthesis of the truncated aberrant EGFR complementary DNA template. Regions of complementary sequence are shown by dotted lines. The 5Ј boundary sequences of exon VII that form the ribozyme cleavable sequence 5Ј-AAGGTAATT-3Ј are shown in bold letters. C) PCR primers used to synthesize the ribozyme. The sense primer Rb3 (38 mer, 5Ј-TAATACGACTCAC-TATAGTCACCACATAATCTGATGAG-3Ј) contains a T7 RNA polymerase promoter sequence and the antisense primer Rb4 (37 mer, 5Ј-GAAAAGAAAGGTTTCGTCCTCACGGACTCATCAGATT-3Ј) contains the hammerhead structure of the ribozyme abEGFR-rib. Regions of complementary sequence are shown by dotted lines.
phosphate precipitation method using 10 g of the plasmid DNA (23) . Plasmidcontaining cells were selected in DMEM supplemented with 500 g/mL of hygromycin for 3 weeks and subsequently isolated using a cloning cylinder.
The level of the abEGFR mRNA was determined by RNA blotting analysis. Total RNAs were extracted from ERM5-1 cells, transfected cell lines 1-21(abEGFR-rib) and 21-16(dis-abEGFR-rib), and normal human placental tissue by a single-step procedure using guanidine thiocyanate and acid phenol/ chloroform (24) . Aliquots of 20 g of total RNA electrophoresed through 1% agarose/6% formaldehyde gels and the RNA transfered onto nylon membranes (GeneScreen Plus; Du Pont NEN, Boston, MA). Immobilized RNAs were hybridized with 32 P-labeled human EGFR cDNA using standard methods and the bands visualized by autoradiography (25) .
Introduction of Ribozyme-Producing Cells Into Nude Mice
ERM5-1 cells, or abEGFR-rib or dis-abEGFR-rib-producing ERM5-1 cells (2 or 8 × 10 4 cells/mouse), were subcutaneously inoculated into nude mice (female, 8 weeks, BALB/cA-nu, Clea Japan Inc., Tokyo). The growth rates of the cells were estimated by measuring the size of the tumor lesions after inoculation. We estimated growth rates for two transfected cell lines (1-21 and 1-26) producing abEGFR-rib and two cell lines (21-12 and 21-16) producing disabEGFR-rib. All experiments involving laboratory animals were performed in accordance with the care and use guidelines of the Central Institute for Experimental Animals.
We estimated the fraction of growing cells by a bromodeoxyuridine (BrdU) incorporation labeling assay. Tumors were surgically removed from the mice under deep anesthesia 2 hours after intraperitoneal injection with 100 mg/kg of BrdU (Sigma Chemical Co.). Tumors were fixed in 10% formalin at room temperature for 24 hours. Sections (2-4-m thick) from each tumor were mounted on glass slides. After blocking of endogenous peroxidase by treating the sections with 2 N HCl (30 minutes, room temperature), each preparation was incubated with 0.05% tyrosine (15 minutes, room temperature) for retrieval of BrdU antigenicity, and incubated with rat monoclonal anti-BrdU antibody (1:40, Sera-Lab, Sussex, U.K.) for 45 minutes. The sections were then incubated with horseradish peroxidase (HRP)-conjugated rabbit anti-rat immunoglobulin G 1:200, Dako, Copenhagen, Denmark) at room temperature for 30 minutes. The products were visualized by HRP reaction with 0.02% 3,3Ј-diaminobenzidine containing 0.005% H 2 O 2 . Nuclei of the cells were counterstained with hematoxylin. The number of BrdU-positive cells was determined by counting 1000 tumor cells in three different visual fields under a light microscope at a magnification of ×400.
Results
Cleavage Activity of Aberrant EGFR Ribozyme In Vitro
We determined the optimal conditions for RNA substrate cleavage activity by incubating abEGFR RNA and abEGFR-rib at 37°C for 18 hours using a constant substrate/ribozyme-ratio of 1:1 and a series of Mg 2+ concentrations (see ''Materials and Methods'' section). If the abEGFR-rib was active, we predicted that the 25-base abEGFR RNA substrate would be cleaved to produce a 13-base 5Јend fragment and a 12-base 3Јend fragment. Both 5Ј-13 base and 3Ј-12 base bands were visible following incubation in 1 mM Mg 2+ . The intensity of the two bands increased in a concentration-dependent manner until reaching a plateau at 2 mM Mg 2+ (Fig. 3, A) . However dis-abEGFR-rib with a single base change in the hammerhead structure did not cleave the abEGFR RNA substrate even in the presence of 40 mM Mg 2+ (Fig. 3, B) . To confirm the enzyme-like activity of the abEGFR-rib, we further characterized the ribozyme reaction. We first evaluated the time required to cleave the substrate RNA. The cleavage products were visible within 30 minutes of starting the reaction and showed a gradual increase up to 18 hours (Fig. 3, C) . In fact, the substrate was almost completely exhausted after 18 hours of incubation (Fig. 3, C) . Next, we examined the effect of different substrate/ribozyme ratios on ribozyme activity. The ribozyme effectively cleaved the substrate at substrate/ribozyme ratios of 2:1, 4:1, and 10:1 in the presence of 5 mM Mg 2+ at 37°C for 18 hours. No ribozyme activity was apparent at a substrate/ ribozyme ratio of 100:1 (Fig. 3, D) .
Effects of Ribozyme-Mediated EGFR mRNA Cleavage on Cellular Growth In Vivo
The expression plasmids pH␤-abEGFR-rib and pH␤-disabEGFR-rib were prepared (Fig. 2 ) and used to transfect ERM5-1 cells (see ''Materials and Methods'' section). We isolated 30 stable cell clones (1-1 to 1-30) transfected with pH␤-abEGFR-rib and 30 stable cell clones (21-1 to 21-30) transfected with pH␤-dis-abEGFR-rib after selection with 500 g/mL hygromycin. Production of abEGFR-rib or dis-abEGFR-rib by the transfected cells was confirmed by a reverse transcriptasecoupled PCR assay (data not shown). Transfected cells had variable levels of either ribozyme. We retained two clones of each type that were the highest producers. In culture, the stable transformant 1-21, transfected with pH␤-abEGFR-rib, demonstrated reduced dendritic processing and was smaller in size compared with the pH␤-dis-abEGFR-rib transfectant 21-12 (Fig. 4, A and  B) . The pH␤-dis-abEGFR-rib transfectant 21-12 had a similar morphology compared with the original cell line, ERM5-1 (data not shown). Steady-state levels of the 8.1 kilobase abEGFR mRNA were decreased in the abEGFR-rib-producing cell line 1-21 compared with ERM5-1 cells (Fig. 5) . In contrast, levels of abEGFR mRNA in the dis-abEGFR-rib-producing cell line, 21-16 were even greater than the levels of abEGFR mRNA detected in the ERM5-1 parent cell line (Fig. 5) . Aberrant EGFR mRNA was not detected in normal human placental tissue (Fig.  5) . The growth rate of the abEGFR-rib-producing cell line, 1-21, was not significantly different from that of dis-abEGFR-ribproducing cell line, , and the parent cell line, ERM5-1, under the cell culture conditions used (data not shown). (Fig. 6) 
cell lines were smaller than tumors derived from the 21-12, 21-16, and ERM5-1 cell lines ( Fig. 6 ; Table 1 ).
The abEGFR-rib transfectant 1-21 showed lower mitotic activity (Fig. 7, A and B) . In addition, the labeling index determined by BrdU incorporation was decreased in the transfectants carrying the ribozyme expression plasmid pH␤-abEGFR-rib compared with cells carrying the disabled ribozyme expression plasmid pH␤-dis-abEGFR-rib (Table 1 ; Fig. 7, C and D) .
Discussion
We previously reported that rearrangement of the EGFR gene frequently results in a loss of genomic DNA that leads to aberrant splicing of nucleotides 275-1075, the first and seventh exons. The resulting 801 nucleotide deletion in EGFR mRNA is associated with transforming activity and malignancy in human malignant gliomas (6) . We also demonstrated that the aberrant EGFR transcript was expressed in proliferating cells in malignant glioma by in situ hybridization (10) .
In this study, we prepared a hammerhead-type ribozyme based on the observation that abEGFR mRNA possesses the sequence 5Ј-AAG GUA AUU-3Ј, which is cleavable by ribozymes near the junction of exon I and exon VII in abEGFR mRNA (Figs. 1 and 2) . We first used ribozymes with 9-base annealing arms in vitro (abEGFR-rib and dis-abEGFR-rib) to ensure substrate-specific cleavage. On the basis of our in vitro results, we used ribozymes with 7-base annealing arms for in vivo experiments (pH␤-abEGFR-rib and pH␤-dis-abEGFR-rib) in an effort to increase ribozyme turnover (binding and dissociation). The length of the homologous sequence between abEGFR-rib and its target RNA was adequate for cleavage of the RNA target in vitro. The ribozyme effectively cleaved the substrate even at low Mg 2+ concentrations (1 mM). Although the physiologic intracellular Mg 2+ concentration is in the range of 0.2-1.0 mM (26), we predicted that the ribozyme would be effective in cleaving abEGFR RNA by using some other divalent cations in vivo. As expected, a disabled ribozyme (disabEGFR-rib) did not cleave the substrate RNA molecule, even at Mg 2+ concentrations as high as 40 mM. These results suggest that the cleavage activity mediated by abEGFR-rib was a ribozyme-specific catalytic reaction rather than a simple antisenseneutralizing reaction in vitro. The cleavage products were detected within 30 minutes of commencement of the reaction and showed a marked increase within 2 hours (Fig. 3, A) . The greater time required for the cleavage reaction by abEGFR-rib suggested that the speed of dissociation of the ribozyme from its reaction complex may be slow compared with proteinaceous enzymes, and that this may represent the rate-limiting step for the cleavage reaction. The abEGFR-rib was effective at a substrate/ribozyme ratio of 4:1 in the presence of 5 mM Mg 2+ at 37°C for 18 hours. The ribozyme retained its activity, even at a substrate/ribozyme ratio of 10:1 (Fig. 3, D) . Taken together, these results suggest that the abEGFR-rib acts as an enzyme-like catalytic molecule in vitro.
When abEGFR-rib-producing ERM5-1 cells were inoculated into nude mice, the introduced cells still formed tumors. However, these tumors were at least one tenth the size of tumors produced by the original ERM5-1 cells or dis-abEGFR-ribproducing cells (Table 1 ). The mitotic activity was also decreased in the abEGFR-rib-producing cell lines. Thus, we confirmed the inhibitory effect of abEGFR-rib on the growth of transformed cells in vivo.
The aberrant EGFR molecule in glioblastomas retains the transmembrane domain and is actually functional as a cellsurface receptor (6) . Most likely, the first exon still encodes the leader sequence of the aberrant EGFR. It is plausible that the mRNA cleaved by the abEGFR-rib may be translated from the next in-frame ''ATG'' codon (theoretically, Met 318 in the fulllength cDNA) to generate a new protein product. This putative new protein is predicted to retain functional domains for signal transduction, although it would not have a leader sequence capable of spanning the cellular membrane. Thus, the protein's intracellular localization may affect signal transduction in relation to cell growth.
On the basis of our results, we conclude that the aberrant EGFR mRNA-specific hammerhead ribozyme described here effectively inhibits cellular growth. Because this deletion in EGFR mRNA is known to be closely associated with malignant gliomas, we think that the ribozyme-mediated specific cleavage of aberrant EGFR transcripts is an elegant approach leading to gene therapy of malignant glioma. 
